论文部分内容阅读
目的探讨匹多莫德对支气管哮喘患儿机体免疫功能及肺功能的影响。方法以2014年10月至2016年4月92例支气管哮喘患儿作为研究对象,根据随机数字表法分为两组,每组46例。对照组予以常规方法治疗,观察组予以匹多莫德进行治疗。对比两组患儿治疗后免疫功能及肺功能变化、临床疗效等。结果治疗后,观察组患儿的CD_4~+/CD_8~+值、CD_8~+、CD_4~+及CD_3~+水平、用力肺活量(FVC)、第1秒用力呼气容积(FEV1)及最大呼气流量(PEF)均优于对照组,治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论采用匹多莫德治疗儿童支气管哮喘的疗效确切,对提高患儿的免疫功能、改善患儿的肺功能具有积极意义,值得临床推广和运用。
Objective To investigate the effect of pidotimod on immune function and pulmonary function in children with bronchial asthma. Methods From October 2014 to April 2016, 92 children with bronchial asthma were selected as study subjects and divided into two groups according to the random number table method, with 46 cases in each group. The control group was treated by conventional methods, and the observation group was treated with Pidotimod. After treatment, the immune function, pulmonary function and clinical efficacy of the two groups were compared. Results After treatment, the levels of CD_4 ~ + / CD_8 ~ +, CD_8 ~ +, CD_4 ~ + and CD_3 ~ +, FVC and FEV1 in the observation group, Gas flow (PEF) were better than the control group, the total effective rate was higher than the control group, the difference was statistically significant (P <0.05). Conclusion Pidotimod treatment of bronchial asthma in children with exact effect, to improve children’s immune function, improve lung function in children with positive significance, worthy of clinical promotion and use.